

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/12, 9/72	A1	(11) International Publication Number: WO 98/56349 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/EP98/03533 (22) International Filing Date: 10 June 1998 (10.06.98) (30) Priority Data: 9712434.1 13 June 1997 (13.06.97) GB (71) Applicant (for all designated States except US): CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): LEWIS, David [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). GANDERTON, Davis [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). MEAKIN, Brian [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). BRAMBILLA, Gaetano [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). GARZIA, Raffaella [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL AEROSOL COMPOSITION (57) Abstract A composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane and a cosolvent. The composition further includes a low volatility component which is added to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. With the addition of the low volatility component, the MMAD of the aerosol particles may be comparable to the MMAD of aerosol particles of an aerosol inhaler including CFC as propellant.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL AEROSOL COMPOSITION

The invention relates to aerosol compositions for pharmaceutical use. In particular, this invention relates to aerosol compositions for use in pressurised metered dose inhalers (MDI). The invention also relates
5 to the use of certain components in aerosol compositions, a method for their preparation and to their use for the administration of active material by inhalation.

Inhalers are well known devices for administering
10 pharmaceutical products to the respiratory tract by inhalation.

Active materials commonly delivered by inhalation include bronchodilators such as $\beta 2$ agonists and anticholinergics, corticosteroids, anti-leukotrienes,
15 anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material.

There are a number of types of inhaler currently
20 available. The most widely used type is a pressurised metered dose inhaler (MDI) which uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. Formulations used in MDIs (aerosol formulations) generally comprise the
25 active material, one or more liquefied propellants and a surfactant or a solvent.

For many years the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or

2

CFCs, such as CCl_3F (Freon 11 or CFC-11), CCl_2F_2 (Freon 12 or CFC-12), and $\text{CClF}_2\text{-CClF}_2$ (Freon 114 or CFC-114). Chlorofluorocarbons have properties particularly suitable for use in aerosols, including high vapour pressure which generates clouds of droplets of a suitable particle size from the inhaler.

Recently, the chlorofluorocarbon (CFC) propellants such as Freon 11 and Freon 12 have been implicated in the destruction of the ozone layer and their production is being phased out.

In 1987, under the auspices of the United Nations Environmental Programme, the Montreal Protocol on Substances that Deplete the Ozone Layer was developed calling for the progressive reduction in CFC use until their elimination.

The aerosol pharmaceutical products for the treatment of asthma and bronchopulmonary diseases are agreed to be essential and enjoy a temporary exemption. However it is believed that the medical use of CFCs will be discontinued in the near future. The ozone-destroying potential of CFCs is proportional to the chlorine content.

Hydrofluoroalkanes [(HFAs) known also as hydrofluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs.

HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems

are disclosed in several patent applications.

Many of these applications, in which HFAs are used as propellant, propose the addition of one or more of adjuvants including compounds acting as cosolvents, surface active agents including fluorinated and non-fluorinated surfactants, dispersing agents including alkylpolyethoxylates and stabilizers.

Cosolvents which may be used in these formulations include alcohols such as ethanol and polyols such as propylene glycol.

Medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777. EP 0372777 requires the use of HFA 134a as a propellant in combination with both a surfactant and an adjuvant having higher polarity than the propellant.

For aerosol suspension compositions, a surfactant is often added to improve the physical stability of the suspension. EP 0372777 states that the presence of surfactant assists in the preparation of stable, homogeneous suspensions and may also assist in the preparation of stable solution formulations.

Surfactants also lubricate the valve components in the inhaler device.

The use of propylene glycol as a solvent having a higher polarity than the propellant in HFA pressurized metered dose inhalers formulations has been mentioned in several other patent applications and for example in:

EP 504112 relates to a pharmaceutical aerosol formulation free from CFCs containing a propellant (hydrocarbon, HFA or a mixture), one or more pharmaceutical active ingredients, a non-ionic

4

surfactant and optionally other conventional pharmaceutical auxiliaries suitable for aerosol formulations comprising solvents having a higher polarity than the propellant, other non-ionic surfactants as valve lubricants, vegetable oils, phospholipids, taste masking agents.

DE 4123663 describes a medical aerosol composition containing a dispersion or suspension of an active agent in association with a compound with surface-active or lipophilic properties, heptafluoropropane as propellant and an alcohol such as ethanol and/or propylene glycol.

U.S. 5,534,242 describes an aerosol-dispensable pharmaceutical composition comprising lidocaine base and a vasoconstrictor dissolved in an HFA propellant and optionally an organic solvent.

Other applications propose the addition of dispersing agents to the composition. U.S. 5,502,076 concerns compositions used in inhalation aerosols comprising an HFA, leukotriene antagonists and dispersing agent comprising 3C-linked triesters, vitamin E acetate, glycerin, t-BuOH, or transesterified oil/polyethylene glycol.

EP 384371, describes a propellant for an aerosol, comprising pressure-liquefied HFA 227 in a mixture with pressure-liquefied propane and/or n-butane and/or isobutane and/or dimethyl ether and/or 1,1-difluoroethane. The document also discloses foam formulations (shaving and shower foams) containing glycerol as additive.

The effectiveness of an aerosol device, for example an MDI, is a function of the dose deposited at the appropriate site in the lungs. Deposition is affected

5

by several factors, of which one of the most important is the aerodynamic particle size. Solid particles and/or droplets in an aerosol formulation can be characterized by their mass median aerodynamic diameter (MMAD, the diameter around which the mass aerodynamic diameters are distributed equally).

Particle deposition in the lung depends largely upon three physical mechanisms: (1) impaction, a function of particle inertia; (2) sedimentation due to gravity; and (3) diffusion resulting from Brownian motion of fine, submicrometer ($< 1 \mu\text{m}$) particles. The mass of the particles determines which of the three main mechanisms predominates.

The effective aerodynamic diameter is a function of the size, shape and density of the particles and will affect the magnitude of forces acting on them. For example, while inertial and gravitational effects increase with increasing particle size and particle density, the displacements produced by diffusion decrease. In practice, diffusion plays little part in deposition from pharmaceutical aerosols. Impaction and sedimentation can be assessed from a measurement of the mass median diameter (MMAD) which determines the displacement across streamlines under the influence of inertia and gravity, respectively.

Aerosol particles of equivalent MMAD and GSD (Geometric Standard Deviation) have similar deposition in the lung irrespective of their composition. The GSD is a measure of the variability of the aerodynamic particle diameters.

For inhalation therapy there is a preference for

6

aerosols in which the particles for inhalation have a diameter of about 0.8 to 5 μm . Particles which are larger than 5 μm in diameter are primarily deposited by inertial impaction in the oropharynx, particles 0.5 to 5 μm in diameter, influenced mainly by gravity, are ideal for deposition in the conducting airways, and particles 0.5 to 3 μm in diameter are desirable for aerosol delivery to the lung periphery. Particles smaller than 0.5 μm may be exhaled.

Respirable particles are generally considered to be those with aerodynamic diameters less than 5 μm . These particles, particularly those with a diameter of about 3 μm , are efficiently deposited in the lower respiratory tract by sedimentation.

It has been recently demonstrated in patients with mild and severe airflow obstruction that the particle size of choice for a β_2 agonist or anticholinergic aerosol should be approximately 3 μm (Zaanen P et al. Int J Pharm 1994, 107:211-7; Int J Pharm 1995, 114:111-5; Thorax 1996, 51:977-980).

Besides the therapeutic purposes, the size of aerosol particles is important in respect to the side effects of the drugs. For example, it is well known that the oropharynx deposition of aerosol formulations of steroids can result in side effects such as candidiasis of mouth and throat.

On the other hand a higher systemic exposure to the aerosol particles due to deep lung penetration can enhance the undesired systemic effects of the drugs. For example, the systemic exposure to steroids can produce side effects on bone metabolism and growth.

It has been reported that the particle size characteristics of HFA aerosol formulations of the state of the art are often very different from the products to be replaced.

5 EP 0553298 describes an aerosol formulation comprising: a therapeutically effective amount of beclomethasone 17,21 dipropionate (BDP); a propellant comprising a hydrofluorocarbon selected from the group consisting of HFA 134a, HFA 227, and a mixture thereof,
10 and ethanol in an amount effective to solubilize the beclomethasone 17,21 dipropionate in the propellant. The formulation is further characterized in that substantially all of the beclomethasone 17,21 dipropionate is dissolved in the formulation and that
15 the formulation contains no more than 0,0005% by weight of any surfactant.

It has been reported in literature that these new formulations of beclomethasone dipropionate (BDP) as a solution in HFA 134a deliver a particle size
20 distribution with a MMAD of 1.1 μm . This means that the peripheral pulmonary deposition of very small particles increases and submicronic particles can easily be directly absorbed from the alveoli into the bloodstream. The rate and extent of systemic absorption is
25 significantly increased and as a consequence undesired effects for example certain side effects can increase. A relatively large fraction of the dose is exhaled. The implications of this for clinical efficacy and toxic effects are great. They arise because the principles of
30 formulation using HFAs may modify the physical form of the respired cloud.

According to the invention there is provided a composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and
5 further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.

The nature and concentration of the low volatility component can be chosen to influence, for example, the
10 size and/or the density of the particle, both of which affect the MMAD.

It is an object of the invention to provide an aerosol formulation which avoids or mitigates the problems indicated above and in particular provides an
15 aerosol composition including HFA as propellant having similar size characteristics to the CFC compositions which they replace. That would help to provide an MDI having HFAs as propellant which was pharmaceutically and clinically equivalent to the MDIs which use CFCs.

20 Although most commonly applied to formulae in which the active agent(s) is in solution, the principle can also be applied to suspension formulae and to mixed formulae in which only one of the components is present in solution form.

25 The invention thus allows the design of formulae using HFAs with similar particle size characteristics to those of the CFC formulations they replace. This allows development of products which are pharmaceutically and clinically equivalent to the CFC formulation.

30 Examples of low volatility components which may be included in the aerosol formulation to increase the MMAD

of the aerosol particles include high density components, for example glycerol and propylene glycol, and low density compounds, for example oleic acid and certain vegetable oils.

5 Glycerol and propylene glycol have previously been investigated as additives in aqueous systems in relation to the nebulization of fluids by jet or ultrasonic nebulizers. The contents of propylene glycol or glycerol in these systems was very high (10-50% v/v). The results
10 were equivocal.

 Davis SS in Int J Pharm 1(2), 71-83, 1978 examined the aerosolization characteristics of two common nebulizers using a propylene glycol-water systems. The output of aerosol solution droplets passed through a
15 max. at 30% vol./vol. propylene glycol; an increased output was paralleled by an increased particle size.

 Davis SS et al. in Int J Pharm 1(2), 85-93, 1978 examined the output of aerosol droplets from a common nebulizer using a water-propylene glycol-ethanol system.

20 In general an increased alcohol content led to an increased total output from the nebulizer. However, much of this output was in the form of solvent vapour and only a modest increase in the output of therapeutically effective aerosol droplets was obtained.

25 Miller WC and Mason JW in J Aerosol Med 4(4), 293-4, 1991 used radioaerosol techniques to determine if adding propylene glycol would improve aerosol delivery of a jet nebulizer in spontaneously breathing normal human subjects. They found no significant differences
30 in either deposition or penetration between saline control and a 20% propylene glycol solution.

10

McCallion et al. in Pharm Res 12(11), 1682-7, 1995 sought to evaluate in three types of jet nebulizer and two ultrasonic devices the influence on the aerosol's size and output characteristics of fluid systems containing water, ethanol, glycerol 10-50% (v/v) solutions, propylene glycol 10-50% (v/v) solutions and silicone fluids 200/0.65 cs - 200/100 cs. The parameters considered were viscosity and surface tension.

Oleic acid has been used in aerosol formulations, in order to improve the physical stability of drug suspensions, as a dispersing agent useful in keeping the suspended particles from agglomerating.

It has now been surprisingly found that in solution formulations of the present application oleic acid can be used either as solubilizer and/or stabilizer of the active ingredient or a low volatility component.

When used as solubilizer/stabilizer the amount of oleic acid can be varied according to the concentration and the characteristics of the active material. When used as low volatility component the percentage concentration of oleic acid should be preferably no less than 0.5% w/w.

In general terms the low volatility component can be any compound, safe and compatible with the propellant system of the invention capable to influence either the size or the density of the aerosol particle so affecting the MMAD.

As it can be noticed from the results reported in the tables, the influence of the low volatility component on the MMAD of the particles is correlated to its density. The higher the density of the low volatile

11

ingredient, the higher the increase of the MMAD of the aerosol particles on actuation of the inhaler.

The applications concerning aerosol formulations using the new propellant systems disclosed in the known prior art seek to overcome problems of stability of the formulations. The present application seeks a solution both for the stability of the formulations and to the therapeutic problems associated with the new medicinal aerosols, as the presence in the formulation of a low volatility ingredient influences the most important factor affecting aerosol delivery to the lung: the aerodynamic mass of the particles.

It has surprisingly been found that by adding a low volatility component to the composition, the MMAD of the aerosol particles on actuation of the inhaler can be increased and thus the compositions may be formulated so that the aerodynamic particle size characteristics are similar to those for the CFC-propellant compositions.

Advantageously, the low volatility component has a vapour pressure at 25°C not more than 0.1 kPa, preferably not more than 0.05 kPa. We have found that with the addition of components having such low vapour pressures, control of the MMAD may be obtained.

It is thought that the addition of the component having a low vapour pressure depresses the atomisable characteristics of the HFA propellant giving larger particles on actuation of the inhaler and after evaporation of the propellant.

The low vapour pressure of the low volatility component is to be contrasted with that of the cosolvent which preferably has a vapour pressure at 25°C not less

than 3 kPa, more preferably not less than 5 kPa.

The cosolvent has advantageously a higher polarity than that of the propellant and the cosolvent is used to increase the solubility of the active material in the propellant.

Advantageously the cosolvent is an alcohol. The cosolvent is preferably ethanol. The cosolvent may include one or more materials.

The low volatility component may be a single material or a mixture of two or more materials.

We have found that glycols are particularly suitable for use as the low volatility component, especially propylene glycol, polyethylene glycol and glycerol.

Other particularly suitable materials are thought to include other alcohols and glycols, for example alkanols such as decanol (decyl alcohol), sugar alcohols including sorbitol, mannitol, lactitol and maltitol, glycofural (tetrahydro-furfuryl alcohol) and dipropylene glycol.

It is also envisaged that various other materials may be suitable for use as the low volatility component including vegetable oils, organic acids for example saturated carboxylic acids including lauric acid, myristic acid and stearic acid; unsaturated carboxylic acids including sorbic acid, and especially oleic acid; saccharine, ascorbic acid, cyclamic acid, amino acids, or aspartame might be used.

The low volatility component may include esters for example ascorbyl palmitate and tocopherol; alkanes for example dodecane and octadecane; terpenes for example

13

menthol, eucalyptol, limonene; sugars for example lactose, glucose, sucrose; polysaccharides for example ethyl cellulose, dextran; antioxidants for example butylated hydroxytoluene, butylated hydroxyanisole; 5 polymeric materials for example polyvinyl alcohol, polyvinyl acetate, polyvinyl pyrrolidone; amines for example ethanolamine, diethanolamine, triethanolamine; steroids for example cholesterol, cholesterol esters.

The amount of low volatility component in the 10 composition depends to some extent upon its density and the amount of active material and cosolvent in the composition. Advantageously, the composition includes not more than 20% by weight of the low volatility component. Preferably the composition includes not more 15 than 10% by weight of the low volatility component.

On actuation of the inhaler, the propellant and the ethanol vaporise but because of the low vapour pressure of the low volatility component, that component generally will not.

20 It is thought that it is preferable for the composition to contain at least 0.2%, preferably at least 1% by weight of the low volatility component. The composition may contain between 1% and 2% by weight.

Most advantageously, the composition is such that, 25 on actuation of the aerosol inhaler in use, the MMAD of the aerosol particles is not less than 2 μm . For some active materials the MMAD is preferably not less than 2.5 μm and for a few formulations, the preferred MMAD will be greater than 3 μm or even greater than 4 μm . As 30 is indicated in the examples below, for one corresponding inhaler formulation using CFC propellants,

14

the MMAD of the aerosol particles is approximately 2.8 μm (see Table 4 below).

Preferred HFA propellants are HFA 134a and HFA 227. The propellant may comprise a mixture of more than one
5 component.

The composition may be in the form of a solution or a suspension or an ultrafine suspension or colloidal solution. The invention is particularly relevant where the composition is a solution but also relates to
10 suspension, in particular those of small particle size. Preferably the composition is a solution.

In some cases a small quantity of water may be added to the composition to improve the solution of the active material and/or the low volatility component in
15 the cosolvent.

The active material may be one or more of any biologically active material which could be administered by inhalation. Active materials commonly administered in that way include β_2 agonists, for example salbutamol
20 and its salts, steroids for example beclomethasone dipropionate or anti-cholergics for example ipratropium bromide.

The invention further provides use of a low volatility component in a composition for an aerosol
25 inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA) and a cosolvent, to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.

30 As indicated above, on actuation of the inhaler, the aerosol particles advantageously have an MMAD of not

15

less than 2 μm , for many formulations more preferably not less than 2.5 μm .

As described above, the low volatility component advantageously has a vapour pressure at 25°C not more
5 than 0.1 kPa.

The invention also provides an inhaler containing the composition in accordance with the invention.

Also provided is a method of filling an aerosol inhaler with a composition, the method comprising
10 filling the following components into the inhaler

- (a) one or more active materials,
- (b) one or more low volatility components,
- (c) one or more cosolvents

followed by the addition of a propellant containing a
15 hydrofluoroalkane (HFA).

The invention further provides aerosol particles emitted from an aerosol inhaler containing a composition, the composition comprising an active component, a propellant containing a hydrofluoroalkane
20 (HFA), a cosolvent and a low volatility component, wherein the mass median aerodynamic diameter (MMAD) of the aerosol particles is not less than 2 μm .

For some compositions, it is preferred that the MMAD of the particles is not less than 2.5 μm as
25 indicated above.

The particles will usually be in the form of droplets.

Embodiments of the invention will now be described by way of example.

30 The aerosol compositions of the invention described below were prepared by the following method. The

16

required components of a composition were added into a can in the following order: drug, non-volatile additive, absolute ethanol. After crimping of the valve on to the can, the propellant was added through the valve. The weight gain of the can after each component was added was recorded to allow the percentage, by weight, of each component in the formulation to be calculated.

The aerodynamic particle size distribution of each formulation was characterized using a Multistage Cascade Impactor according to the procedure described in the European Pharmacopoeia 2nd edition, 1995, part V.5.9.1. pages 15-17. In this specific case an Andersen Cascade Impactor (ACI) was used. Results represented were obtained from ten cumulative actuations of a formulation. Deposition of the drug on each ACI plate was determined by high pressure liquid chromatography. The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were calculated from plots of the cumulative percentage undersize of drug collected on each ACI plate (probit scale), against the upper cut off diameter for each respective ACI plate (log10 scale). The fine particle dose of each formulation was determined from the mass of drug collected on Stages 2 through to Filter ($< 5.8 \mu\text{m}$) divided by the number of actuations per experiment.

Tables 1 and 2 show comparative examples indicating the characteristics of aerosol formulations containing HFA 134a, different beclomethasone dipropionate (BDP) (active material) amounts and different ethanol concentrations. The formulations do not contain a low volatility component. As can be seen, the MMAD is not

17

substantially influenced by the ratio of cosolvent to propellant.

Increase of the concentration of the active ingredient gives a slight variation of MMAD which, in this case, is correlated with the BDP content.

For equal concentrations of BDP the content of ethanol and the addition up to 0.5% of water does not significantly affect the MMAD.

Table 3 compares the characteristics of a CFC ipratropium bromide (IPBr) standard formulation with HFA 134a, ethanol, ipratropium bromide solution formulations with a content of glycerol from 0 to 1%.

It can be seen that the MMAD of the formulation having the HFA as propellant is significantly lower than that for the conventional CFC formulation.

The MMAD of the HFA/ethanol-IPBr formulations is 1.2 ± 1.9 or 1.3 ± 0.1 μm depending on the content of ethanol (respectively $12.9 \pm 0.1\%$ w/w and 25% w/w), in comparison with an MMAD of 2.8 ± 0.1 μm of the CFC-IPBr formulation.

The addition of a low volatile additive such as glycerol increases the particle MMAD of the HFA solution formulations; the increase is correlated with the glycerol concentration.

In confirmation of the results of Tables 1 and 2 the MMAD is not substantially influenced by the ratio of cosolvent to propellant.

In other studies the effects of increasing concentrations of propylene glycol, glycerol and polyethylene glycol (PEG) in HFA 134a and ethanol beclomethasone dipropionate (BDP) formulations have been

determined.

The % indicated for the components of the composition are % by weight unless indicated to the contrary.

5 The results are reported in Tables 4, 5, 6, 7 and 8.

10 The results show the direct relationship between the percentage of low volatile ingredient and particle MMAD. As we can notice there is a slight influence of the actuator orifice on the MMAD but the relationship between the concentration of low volatile ingredient and particle MMAD is maintained. These findings demonstrate that the addition of an established amount of low volatile additives in HFA formulations can increase the MMAD of the particles to values comparable to the MMAD of the previously known CFC formulations which the HFA formulations seek to replace.

15 Advantageously, the GSD is not significantly changed on addition of the low volatility component. In particular, for glycerol as the low volatility component, Tables 6 and 7 show that the GSD is not substantially changed by the addition of glycerol. Glycerol is a particularly preferred material for the low volatility component.

20 The increase in particle MMAD by the addition of an established amount of glycerol in HFA solution formulation has been observed also with flunisolide (Table 9), in the presence of a moderate concentration of a taste corrective such as menthol.

25 Analogous results have been obtained with salbutamol, as it can be noticed in Table 10. A small

amount of oleic acid (0.3%) has been added to the formulation to improve the physical stability of the solution. In this concentration the oleic acid does not substantially modify the particle MMAD of the active material.

In Table 11 HFA 134a, ethanol 15.4±0.2%, BDP in combination with salbutamol formulations without and in presence of 1.2% of glycerol and with a content of oleic acid from 0 to 1.3% are compared.

The results show that:

- a) the MMAD of the two active materials in solution combination without low volatility components is practically the same as the single compounds;
- b) oleic acid in concentration of 1.3% acts as low density low volatile compound and produces an appreciable increase in particle MMAD;
- c) the influence of the low volatility component of the MMAD is correlated to its density; oleic acid in concentration of 1.3% produces an increase in MMAD to a definitely less extent than 1.2% of glycerol, which has a higher density;
- d) the presence in the formulation of two active materials, the low volatility ingredient and the stabilizer, does not cause any interference between the components.

Oleic acid is another preferred material for a low density low volatility component.

Finally, Table 12 shows that the addition of a low volatility component allows the modulation of the MMAD of an active material formulated as a solution in an HFA 227/ethanol system.

20

Therefore, the formulations of the invention allow improvement of the delivery characteristics of drugs to the lung by modulating the aerodynamic particle size and size distribution so that the pattern of deposition gives an equivalent clinical effect.

5

Table 1: BDP formulations in HFA 134a and ethanol - Actuator orifice 0.25 mm

	BDP 10mg/10ml ethanol 7.9%	BDP 10mg/10ml ethanol 12.9- 13.0%	BDP 20mg/10ml ethanol 7.9%	BDP 20mg/10ml ethanol 13.0%
Mean emitted dose (μ g)	44.7	45.1	84.8	87.6
Fine particle dose (μ g)	31.1	24.5	63.1	46.2
MMAD \pm GSD	0.8 \pm 1.8	0.9 \pm 2.0	1.0 \pm 1.8	1.0 \pm 1.9
Shot weight(mg)	59.0	58.7	59.1	57.6
Replications	6	2	6	2

Table 2: BDP formulations in HFA 134a, ethanol and small amounts of water (up to 0.5%)
 - Actuator orifice 0.33 mm

	BDP 10mg/10ml ethanol 13.7% H ₂ O 0.1%	BDP 10mg/10ml ethanol 13.6% H ₂ O 0.5%	BDP 50mg/10ml ethanol 14.9% H ₂ O 0.1%	BDP 50mg/10ml ethanol 14.9% H ₂ O 0.5%
Mean emitted dose (µg)	43.2	42.9	222.1	215.1
Fine particle dose (µg)	14.9	12.7	67.4	60.2
MMAD (µm) ± GSD	1.0 ± 2.2	1.0 ± 2.1	1.8 ± 2.2	1.7 ± 2.2
Shot weight (mg)	58.1	58.0	59.0	57.5
Replications	6	6	6	6

22

Table 3: Comparison of standard CFC ipratropium bromide formulation (4 mg/10 ml IPBr) and HFA 134a/ethanol-ipratropium bromide solution without and in presence of increasing amount of glycerol

Formulations	CFC-IPBr	HFA 134a/ethanol 25% - IPBr **	HFA 134a-IPBr *
Glycerol content (%)		0	0
Mean emitted dose (μ g)	18.8	17.1	16.1
Fine particle dose (μ g)	6.1	2.6	3.9
MMAD (μ m) \pm GSD	2.8 \pm 1.8	1.3 \pm 2.0	1.2 \pm 1.9
Shot weight (mg)	75.4	55.7	58.0
Replications	3	4	6
			0.5
			18.7
			6.9
			1.9 \pm 2.0
			59.0
			58.3
			2.5 \pm 2.1
			6

23

* HFA formulation: 4 mg/10 ml IPBr; ethanol 12.9 \pm 0.1% (w/w); HFA 134a fill to 12 ml.

** IPBr 4 mg/10 ml; HFA 134a fill to 12 ml

Actuator orifice: 0.33 mm

Table 4: Comparison of BDP formulations in HFA 134a and ethanol in the presence of increasing amount of propylene glycol

	Propylene glycol content			
	0.0 % (w/w)	1.1 % (w/w)	3.2 % (w/w)	6.8 % (w/w)
Mean emitted dose (μ g)	41.8	44.0	43.6	44.9
Fine particle dose (μ g)	10.3	9.3	7.3	4.9
MMAD (μ m) \pm GSD	1.1 \pm 2.3	1.6 \pm 3.4	2.9 \pm 4.1	4.6 \pm 3.9
Replications	2	6	6	6

24

Formulation: BDP 10 mg / 10 ml; ethanol 12.9 \pm 0.1% (w/w); HFA 134a fill to 12 ml.
 Actuator orifice: 0.42 mm

Table 5 : Comparison of BDP formulations in HFA 134a and ethanol in the presence of increasing amount of propylene glycol

	Propylene glycol content			
	0.0 % (w/w)	0.7 % (w/w)	2.8 % (w/w)	6.3 % (w/w)
Mean emitted dose (μg)	209.1	218.4	204.2	242.6
Fine particle dose (μg)	41.6	41.1	32.1	25.2
MMAD (μm) \pm GSD	1.7 \pm 2.3	2.1 \pm 2.7	3.3 \pm 3.2	4.4 \pm 3.8
Replications	3	3	3	3

Formulation: BDP 50 mg / 10 ml; ethanol 15.2 \pm 0.4% (w/w); HFA 134a fill to 12 ml.
 Actuator orifice: 0.42 mm

Table 6: Comparison of BDP formulations in HFA 134a and ethanol in the presence of increasing amount of glycerol

	Glycerol content			
	0.0% (w/w)	1.0% (w/w)	1.3% (w/w)	1.6% (w/w)
Mean emitted dose (μg)	205.8	218.3	220.8	228.0
Fine particle dose (μg)	105.9	94.4	100.3	96.6
MMAD (μm) \pm GSD	1.4 \pm 1.9	2.4 \pm 2.0	2.6 \pm 2.0	2.7 \pm 2.0
Replications	6	3	3	2

Formulation: BDP 50 mg/10 ml; ethanol 15.0 \pm 0.2% (w/w); HFA 134a fill to 12 ml

Actuator orifice: 0.25 mm

Table 7: Comparison of BDP formulations in HFA 134a and ethanol in the presence of increasing amount of glycerol

	Glycerol content			
	0.0% (w/w)	1.0% (w/w)	1.3% (w/w)	1.6% (w/w)
Mean emitted dose (μg)	222.1	227.9	228.4	231.7
Fine particle dose (μg)	67.4	55.9	54.3	50.9
MMAD (μm) \pm GSD	1.8 \pm 2.2	2.8 \pm 2.2	3.1 \pm 2.3	3.1 \pm 2.3
Replications	6	4	3	2

Formulation: BDP 50 mg/10 ml; ethanol 15.0 \pm 0.2% (w/w); HFA 134a fill to 12 ml

Actuator orifice: 0.33 mm

Table 8: Comparison of BDP formulations in HFA 134a and ethanol in the presence of polyethylene glycol (PEG) 400 or 8000

	PEG 400	PEG 8000	
	1.1% (w/w)	1.0% (w/w)	0.0% (w/w)
Mean emitted dose (μg)	218.9	215.0	222.1
Fine particle dose (μg)	55.6	55.6	67.4
MMAD (μm) \pm GSD	2.5 \pm 2.2	2.5 \pm 2.2	1.8 \pm 2.2
Replications	2	1	6

Formulation: BDP 50 mg/10 ml; ethanol 14.9 \pm 0.1% (w/w); HFA 134a fill to 12 ml

Actuator orifice: 0.33 mm

Table 9: Comparison of Flunisolide solution formulations in HFA 134a and ethanol without and in presence of glycerol

Menthol % (w/w)	Glycerol % (w/w)	Fine Particle Dose (FPD) (µg)	MMAD	GSD	Emitted Dose (µg)	Replications (n)
0	0	76.85	1.8	2.15	217.1	2
0.4	0.9	77.84	2.9	2.1	221.6	5

29

Formulation: Flunisolide 50 mg/10 ml; ethanol 15.0 ± 0.1%; HFA 134a fill to 12 ml

Actuator orifice: 0.30 mm

Table 10: Comparison of Salbutamol base solution formulations in HFA 134a and ethanol without and in presence of glycerol

Glycerol & (w/w)	Oleic Acid & (w/w)	Emitted dose (µg)	FPD (µg)	MMAD (µm)	GSD	Replications (n)
0	0.35	85.8	29.1	1.7	2.3	1
1.3	0.36	92.0	25.2	2.8	2.4	1

30

Formulation: Salbutamol base 20mg/10ml; ethanol 15% (w/w); HFA 134a fill to 12ml
Actuator, orifice: 0.30mm

Table 11: BDP and Salbutamol base combination in solution formulations in HFA 134a and ethanol, without and in presence of glycerol, oleic acid and their combination

Glycerol % (w/w)	Oleic Acid % (w/w)	BDP			Salbutamol Base				Actuator exit orifice (mm)	n	
		Emitted dose (µg)	FPD (µg)	MMAD (µm)	GSD	Emitted dose (µg)	FPD (µg)	MMAD (µm)			GSD
0	0	208.9	67.8	1.7	2.4	82.5	26.9	1.7	2.2	0.33	2
0	0.3	212.7	60.6	2.2	2.3	84.8	24.0	2.0	2.6	0.33	2
0	1.3	212.5	58.5	2.4	2.2	85.9	23.9	2.4	2.1	0.30	1
1.2	0.3	210.8	63.3	2.9	2.1	85.3	25.1	3.0	2.0	0.30	1

Formulation: BDP 50 mg/10 ml; Salbutamol base 20 mg/10 ml; ethanol 15.4 ± 0.2% (w/w);

HFA 134a fill to 12 ml

Table 12: BDP 50mg/10ml formulations in HFA 227 and ethanol 15.0±0.2% (w/w), with and without glycerol as a non volatile additive. HFA 227 fill to 12ml; Actuator orifice 0.33mm

	HFA 227	
	0% (w/w) Glycerol	1.42% (w/w) Glycerol
FPD (µg)	62.1	43.5
MMAD (µm)	2.2	4.1
GSD	2.6	2.4
Mean emitted dose (µg)	221.25	230.5
Replications	2	2

CLAIMS

1. A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant
5 containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
2. A composition according to claim 1, wherein the low
10 volatility component has a vapour pressure at 25°C not more than 0.1 kPa.
3. A composition according to claim 2, wherein the low volatility component has a vapour pressure at 25°C not more than 0.05 kPa.
- 15 4. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25°C not less than 3 kPa.
5. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25°C not
20 less than 5 kPa.
6. A composition according to any preceding claim, wherein the cosolvent is an alcohol.
7. A composition according to any preceding claim, wherein the low volatility component includes a glycol.
- 25 8. A composition according to any preceding claim, wherein the low volatility component includes oleic acid.
9. A composition according to any preceding claim, wherein the propellant includes one or more HFAs
30 selected from the group comprising HFA 134a and HFA 227.
10. A composition according to any preceding claim,

wherein the composition includes not more than 20% by weight of the low volatility component.

11. A composition according to any preceding claim, wherein the composition includes at least 0.2% by weight of the low volatility component.

12. A composition according to any preceding claim, the composition being such that, on actuation of the aerosol inhaler in use, the MMAD of the aerosol particles is not less than 2 μm .

13. A composition according to any preceding claim, wherein the composition is in the form of a solution.

14. Use of a low volatility component in a composition for an aerosol inhaler, the composition comprising an active material, a propellant containing hydrofluoroalkane (HFA) and a cosolvent, to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.

15. Use of a low volatility component according to claim 14 to give a MMAD of the aerosol particles of not less than 2 μm .

16. Use of a low volatility component according to claim 14 or claim 15, wherein the low volatility component has a vapour pressure at 25°C not more than 0.1 kPa.

17. Use of a low volatility component according to any of claims 14 to 16, the composition being as claimed in any of claims 1 to 13.

18. An aerosol inhaler containing a composition, the composition being as claimed in any of claims 1 to 13.

19. Method of filling an aerosol inhaler with a composition, the method comprising filling the following

35

components into the inhaler

- (a) one or more active materials,
- (b) one or more low volatility components,
- (c) one or more cosolvents

5 followed by the addition of a propellant containing a hydrofluoroalkane (HFA).

20. A method according to claim 19, the composition being as claimed in any of claims 1 to 13.

21. Aerosol particles emitted from an aerosol inhaler
10 containing a composition, the composition comprising an active component, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and a low volatility component, wherein the mass median aerodynamic diameter (MMAD) of the aerosol particles is
15 not less than 2 μm .

22. Aerosol particles according to claim 21, wherein the MMAD of the particles is not less than 2.5 μm .

23. Aerosol particles according to claim 21 or claim 22, wherein the composition is according to any of
20 claims 1 to 13.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP98/03533

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 9/12, A 61 K 9/72

According to International Patent Classification (IPC) or to both national classification and IPC 6

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 4123663 A1 (DR. WILLMAR SCHWABE GMBH & CO) 21 January 1993 (21.01.93), claims 1-8, examples 1-3 (cited in the application). --	1-23
X	EP 0372777A2 (RIKER LABORATORIES, INC.) 13 June 1990 (13.06.90), claims 1-10, page 4, lines 16-22, page 5, lines 41-46 (cited in the application). --	1-12, 14-23
X	WO 92/08446 A1 (GLAXO GROUP LTD) 29 May 1992 (29.05.92), claims 1-8, page 3, lines 1- 3, page 4, last paragraph.	1-12, 14-18, 21-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

01 October 1998

Date of mailing of the international search report

06.11.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP98/03533

-2-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 93/11747 A1 (MINNESOTA MINING AND MANUFACTURING COMPANY) 24 June 1993 (24.06.93), abstract, claims 1-4, 15, page 8, line 24 - page 9, line 18, page 9, lines 26-36, examples 10, 14.</p>	1-6, 8-12, 14-23
X	<p>EP 0518601 A1 (SCHERING CORPORATION) 16 December 1992 (16.12.92), claims 1-3, 7-12, page 2, lines 3-5, page 3, lines 10-51, page 4, line 34 - page 5, line 10, page 5, lines 34-36, 45-56.</p>	1-18, 21-23
X	<p>EP 0518600 A1 (SCHERING CORPORATION) 16 December 1992 (16.12.92), claims 1-3, 7-12, page 2, lines 3-5, page 3, lines 11-58, page 4, line 45 - page 5, line 22, page 5, lines 46-48.</p>	1-18, 21-23
X	<p>WO 94/13262 A1 (JAGER, P.D. et al.) 23 June 1994 (23.06.94), abstract, claims 1-4, 6, 8-10, 12, page 4, line 19 - page 5, line 11, page 5, line 22 - page 6, line 14, page 9, line 17 - page 10, line 11, page 10, lines 17-32.</p>	1-6, 8-18, 21-23
X	<p>WO 93/11745 A1 (GLAXO GROUP LTD) 24 June 1993 (24.06.93), claims 1, 2, 9, 10, 14, page 5, lines 19-21.</p>	1-7, 9-12, 14-18, 21-23
X	<p>EP 0384371 A1 (HOECHST AKTIENGESELLSCHAFT) 29 August 1990 (29.08.90), abstract, claim 5, example 3 (cited in the application).</p>	1-7, 9-23
X	<p>EP 0504112 A2 (CIBA-GEIGY AG) 16 September 1992 (16.09.92), claims 1-4, page 3, lines 53-</p>	1-7, 9-12, 14-23

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP98/03533

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	54, page 5, lines 10-15, 27-36, page 6, lines 6-25 (cited in the application). -----	

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/EP 98/03533 SAE 202748

In diesem Anhang sind die Mitglieder
der Patentfamilien der im obenge-
nannten internationalen Recherchenbericht
angeführten Patentedokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

Im Recherchenbericht angeführtes Patentedokument in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
DE A1	4123663	21-01-93	keine - none - rien	
EP A2	372777	13-06-90	AU A1 45956/89	14-06-90
			AU B2 6311155	19-11-92
			CA AA 2004598	06-06-90
			DE CO 68904300	18-02-93
			DE T2 68904300	29-04-93
			DE CO 68924540	16-11-95
			DE T2 68924540	15-05-96
			DK AO 5957/89	27-11-89
			DK A 5957/89	07-06-90
			EP A3 372777	22-11-90
			EP A3 499344	19-08-93
			EP A3 499344	02-09-93
			EP B1 372777	07-01-93
			EP A2 653204	17-05-95
			EP B1 499344	11-10-95
			EP A3 653204	15-11-95
			ES T3 2045470	16-01-94
			ES T3 2077971	01-12-95
			GB AO 8828477	05-01-89
			HK A 71/96	26-01-96
			HK A 804/97	20-06-97
			IL AO 92457	31-08-90
			IL A1 92457	21-10-94
			JP A2 2200627	08-08-90
			JP B2 2786493	13-08-98
			MX B 174127	21-04-94
			NZ A 231579	25-11-93
			NZ A 243056	25-11-93
			US A 5225183	06-07-93
			US A 6674473	07-10-97
			US A 6833677	04-11-97
			US A 695743	09-12-97
			US A 7220940	24-02-98
			US A 766573	16-06-98
			US A 776434	07-07-98
			ZA A 909290	26-06-91
			US A 439670	08-08-95
			US A 5605674	25-02-97
			US A 5681545	28-10-97
WO A1	9208446	29-05-92	AT E 127013	15-09-95
			AU A1 88778/91	11-06-93
			AU B2 660952	13-07-95
			CA AA 2094726	10-05-93
			DE CO 691112637	05-10-95
			DE T2 691112637	08-02-96
			DK T3 556256	06-11-95
			EP A1 556256	23-08-93
			EP B1 556256	30-08-93
			ES T3 2078551	16-12-95
			GB AO 9024365	02-01-91
			GR T3 3018172	29-02-96
			JP T2 6501700	24-02-94
WO A1	9311747	24-06-93	AT E 150296	15-04-97
			AU A1 327287/93	19-07-93
			AU B2 6756333	13-02-97
			CA A1 123427/97	20-03-97
			DE CO 69218455	24-04-97
			DE T2 69218455	23-10-97
			DK T3 617610	06-10-97
			EP A1 617610	05-10-94
			EP A2 717987	26-06-96
			EP A3 717987	03-07-96
			EP B1 617610	19-03-97
			ES T3 2099415	16-05-97
			GR T3 3022874	30-06-97
			JP T2 7502275	09-03-95
			NZ A 246421	28-05-96

TEST AVAILABLE COPY

EP A1 518601 16-12-92

AT	E	1323368	15-01-96
AU	A1	21789792	12-01-93
CA	AA	21111002	12-01-93
CN	A	1067578	06-01-92
CZ	A3	93002714	13-07-94
DE	CO	6922007409	15-02-96
EP	A1	5877790	24-03-94
EP	A1	66532055	17-05-95
EP	A1	66532055	07-06-95
EP	B1	5877790	03-01-96
FI	A	9335463	07-12-94
FI	A0	9335463	07-12-94
HU	A2	6744453	28-04-95
IL	A0	10211300	14-01-93
JP	T2	65111235	14-09-94
MX	A1	92002750	28-01-93
NO	A	9334499	09-13-93
NO	A0	9334499	09-13-93
NZ	A	2430062	27-09-93
QA	A	98227	15-04-94
SK	A3	1405793	09-11-94
ZA	A	9204163	24-02-93
WD	A1	9222287	23-12-92

EP A1 518600 16-12-92

AT	E	134509	15-03-96
AU	A1	20175792	12-01-93
CA	AA	21111002	12-01-93
CN	A	1067578	06-01-92
CZ	A3	93002714	13-07-94
DE	CO	6922008660	04-04-96
DE	T2	6922008660	11-07-96
DK	T2	6922008660	18-03-96
EP	A1	5877790	30-03-94
EP	A1	66532006	07-06-95
EP	A1	66532007	07-06-95
EP	B1	5877790	28-02-96
ES	T2	20084360	01-05-96
FI	A	9335464	07-12-94
FI	A0	9335464	07-12-94
GR	T2	30119374	30-06-96
HK	A	1855796	11-10-96
HU	A2	674449	28-04-95
IL	A0	1021131	14-01-93
JP	T2	65111235	15-12-94
MX	A1	92002750	28-01-93
NO	A	9334500	09-13-93
NO	A0	9334500	09-13-93
NZ	A	2430061	27-09-93
QA	A	9868	15-08-94
SK	A3	1404793	09-10-94
ZA	A	9204164	24-02-93
WD	A1	9222288	23-12-92
US	A	5474759	12-12-95

WD A1 9413262 23-06-94

AU	A1	57405794	04-07-94
AU	A1	60486794	04-07-94
AU	B2	6802227	24-07-97
BG	A	997760	29-02-96
CN	A	10952265	24-11-94
CZ	A3	95014900	13-12-95
EP	A1	66733240	27-09-95
FI	A	9335464	09-06-95
FI	A0	9335464	09-06-95
GB	A0	95111669	23-08-95
GB	A1	22288978	08-11-95
GB	B2	22288978	09-04-97
HU	A0	9501166	28-08-95
HU	A2	72985	28-06-96
JP	T2	8509459	08-10-96
LV	A	109111	20-12-95
LV	B	109111	20-04-96
NO	A	9522269	08-06-95
NO	A0	9522269	08-06-95
NZ	A	2559192	26-05-97
PL	A1	30093334	02-10-95
SK	A3	7607995	08-01-97
WD	A1	9413263	23-06-94
ZA	A	9309195	08-06-95
US	A	5676930	14-10-97

WD A1 9311745

AP	A0	9200461	31-01-94
AP	B	4027	12-08-93
AT	E	1283300	15-10-93
AT	E	1633539	15-03-98
AU	A1	60850792	19-07-94
AU	A1	60851192	19-07-94
AU	A1	60852192	19-07-94
AU	B2	66339004	26-10-95
AU	B2	66339005	26-10-95
AU	B2	66339006	26-10-95
BG	A	9988003	28-02-96
CN	A	1075078	11-08-94
CN	A	1075079	11-08-94
CY	A	2008	20-02-95
CZ	A3	9401430	15-04-95

[illegible]